. 2023 Oct 30;5:1239175. doi: 10.3389/frph.2023.1239175

Table 2.

Overall outcome of COS comparison between TAIL and control group.

	TAIL	Control	p-value^***
Number of patients	68	81
Number of COC^*	10.5 (5.5–19)	14 (11 -21)	0.0031^a
Number of MII^*	9 (4 -13)	12 (9–17)	<0.001^a
Total cost of gonadotropins (€)^*	609.77	812.27 (756.02–913.52)	<0.0001^a
MII/€^*	0.01 (0.01–0.02)	0.01 (0.01–0.02)	0.65^a
Categorized “Number of MII”	47 (69.11%)	76 (93.83%)	0.00014^b
(n MII ≥ 6)^**	47 (69.11%)	76 (93.83%)
Categorized “Number of MII”	21 (30.88%)	5 (6.17%)
(n MII < 6)^**	21 (30.88%)	5 (6.17%)
Categorized “Number of MII”	61 (89.7%)	80 (98.8%)	0.024^b
(n MII > 0)^**	61 (89.7%)	80 (98.8%)
Categorized “Number of MII”	7 (10.3%)	1 (1.2%)
(n MII = 0)^**	7 (10.3%)	1 (1.2%)
Number of MII (oocyte retrieval >0) ^*	10 (6–14) (n = 61)	12 (9–17.25) (n = 80)	0.006^a

COC, Cumulus-oocyte complexes; MII, Metaphase II oocytes; €, Euros.

^{^a}

Wilcoxon rank sum test.

^{^b}

Fisher's exact test.

Values are expressed as Median (Interquartile range).

^**

Values are expressed as number (Percentage).

^***

p < 0.05 is significant.